FDA updates guidance for generic makers of top GLP-1 weight-loss drugs
The FDA has released a revised draft guidance aimed at companies that want to develop generic versions of leading weight-loss medications.
The update focuses on products such as Eli Lilly's Zepbound and Novo Nordisk's Ozempic, which are among the highest-selling GLP-1 therapies worldwide.
The agency's changes clarify the data and study requirements that generic developers must meet to demonstrate bioequivalence and safety, potentially streamlining the approval pathway.
Industry observers say the guidance could accelerate market entry for lower-cost alternatives, though manufacturers will still need to address complex manufacturing and clinical considerations.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA offers updated guidance for generics of weight loss blockbusters”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that